Evaluating use characteristics for the oncotype dx 21-gene recurrence score and concordance with chemotherapy use in early-stage breast cancer.
about
Classification of patients with breast cancer according to Nottingham prognostic index highlights significant differences in immunohistochemical marker expression.Quantitative Gene Expression by Recurrence Score in ER-Positive Breast Cancer, by Age.The value of multigene predictors of clinical outcome in breast cancer: an analysis of the evidenceBreast cancer multigene testing trends and impact on chemotherapy use.21-Gene Recurrence Score Assay As a Predictor of Adjuvant Chemotherapy Administration for Early-Stage Breast Cancer: An Analysis of Use, Therapeutic Implications, and Disparity Profile.Adoption of Gene Expression Profiling for Breast Cancer in US Oncology Practice for Women Younger Than 65 Years.Patterns of 21-gene assay testing and chemotherapy use in black and white breast cancer patients.Recommendations from the EGAPP Working Group: does the use of Oncotype DX tumor gene expression profiling to guide treatment decisions improve outcomes in patients with breast cancer?Decision-making impact on adjuvant chemotherapy allocation in early node-negative breast cancer with a 21-gene assay: systematic review and meta-analysis.Oncologist and organizational factors associated with variation in breast cancer multigene testing.ONCOLOGISTS' BARRIERS AND FACILITATORS FOR ONCOTYPE DX USE: QUALITATIVE STUDY.Estimating the OncotypeDX score: validation of an inexpensive estimation tool.Associations between use of the 21-gene recurrence score assay and chemotherapy regimen selection in a statewide registry.Diffusion-weighted MRI characteristics associated with prognostic pathological factors and recurrence risk in invasive ER+/HER2- breast cancers.Oncotype Dx assay and breast cancer in the United States: usage and concordance with chemotherapy.Practice patterns and outcomes for patients with node-negative hormone receptor-positive breast cancer and intermediate 21-gene Recurrence Scores.Gene expression profiling in prognosis of distant recurrence in HR-positive and HER2-negative breast cancer patients.
P2860
Q34042565-9C843ACE-6B54-49C3-BD8D-9248A7088E07Q36373733-1AA2744D-3E02-41C5-A88D-206E6848277AQ36462893-5B09B330-2BD9-4502-A4EE-DDA8B779EF26Q37083264-CE4DE77C-8C16-4D64-BFF2-3B7BC0C20AECQ37138266-34371C47-F604-4919-A377-B62104D0DBE7Q37151779-3D51F53D-A921-42FB-8A03-A2A3EE640FFEQ37606937-83BB3A2E-B9EB-4C88-948E-8DB1E9C12CE7Q38383042-518BA82F-BD38-4786-96A0-0844B8F2A125Q38540963-CC1063C1-2F16-4B5D-8848-55756AE9CF15Q38948829-A84AEEA6-62B8-4F1F-929C-94BB67452966Q39106167-FB668AAA-3C4F-4F4F-96EC-0EF34DDC8457Q39121120-07DF8535-7428-4F8C-83FC-93E2D5B364DDQ39243861-E4E9B825-C5B3-4078-8926-4821008CF65CQ47409196-8DD1064E-3BA7-4A5F-881E-29E16A873435Q51035386-88723058-FF3E-4164-A5DE-C0CDC6BEA016Q52585073-A783A3BE-77FE-4B02-8CDF-8905A9679E91Q54963147-0C45DCC5-6A42-448C-A2D6-229229BA49C3
P2860
Evaluating use characteristics for the oncotype dx 21-gene recurrence score and concordance with chemotherapy use in early-stage breast cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 12 February 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Evaluating use characteristics ...... in early-stage breast cancer.
@en
Evaluating use characteristics ...... in early-stage breast cancer.
@nl
type
label
Evaluating use characteristics ...... in early-stage breast cancer.
@en
Evaluating use characteristics ...... in early-stage breast cancer.
@nl
prefLabel
Evaluating use characteristics ...... in early-stage breast cancer.
@en
Evaluating use characteristics ...... in early-stage breast cancer.
@nl
P2093
P2860
P356
P1476
Evaluating use characteristics ...... in early-stage breast cancer.
@en
P2093
Clara Chen
Debra A Patt
Michael Forsyth
Rahul Dhanda
Wan-Yu Tseng
P2860
P304
P356
10.1200/JOP.2012.000638
P407
P577
2013-02-12T00:00:00Z